The artificial intelligence (AI)-powered Neuro Suite reportedly enables radiologists to access leading neurological AI algorithm solutions in the field, including the brain magnetic resonance imaging (MRI) segmentation capabilities of the Combinostics’ algorithm that can help differentiate degenerative pathologies such as Alzheimer’s disease and dementia.
Emphasizing timely neurological disease triage and access to “a first-in-class capability and the only open (artificial intelligence) AI architecture” for clinical AI, ConcertAI’s TeraRecon has launched Neuro Suite.
The Neuro Suite platform allows radiologists to access a variety of AI-powered neuroimaging modalities from leading vendors in the neurology field, including Combinostics, Imaging Biometrics and Cercare Medical, according to TeraRecon.
For the diagnosis of degenerative cerebral pathologies including Alzheimer’s disease and dementia, the Combinostics algorithm offers high-quality segmentation of brain magnetic resonance imaging (MRI) to help assess atrophy. TeraRecon said the algorithm from Imaging Biometrics provides radiologists with insights into the blood supply and oxygenation of brain tumors. Access to the proprietary perfusion technology of Cercare Medical enables neurovascular function assessment down to the capillary level, according to TeraRecon.
“We are proud to enhance our neurological offerings beyond TR Neuro to an entire Neuro Suite, extending to our clinician customers an amazing array of tools streamlined into one place and able to be interacted with to help identify and treat critical neurological issues,” said Dan McSweeney, the president of TeraRecon.
(Editor’s note: For related content, see “TeraRecon Launches AI-Driven Neuroimaging Platform” and “FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting.”)
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.